Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. (26th December 2017)

• Record Type: Journal Article
• Authors: Fargnoli, M.C.; Ibbotson, S.H.; Hunger, R.E.; Rostain, G.; Gaastra, M.T.W.; Eibenschutz, L.; Cantisani, C.; Venema, A.W.; Medina, S.; Kerrouche, N.; Pérez‐Garcia, B.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 32:Number 5(2018)
• Page Start: 757
• Page End: 762
• Publication Date: 2017-12-26
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.14691
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: Guidelines recommend treating actinic keratoses (AKs) as they are recognized as precursors of invasive squamous cell carcinoma. Objective: The objective of this study was to collect real‐world clinical data on the use of methyl aminolevulinate daylight photodynamic therapy (MAL DL‐PDT) for the treatment of face and scalp AK in Europe. Methods: A prospective, multicenter, non‐interventional study was conducted in six European countries in patients receiving a single treatment of MAL DL‐PDT for face and/or scalp AK. Patient‐reported outcomes were assessed by patient questionnaires at baseline and at 3 months after treatment, efficacy was assessed at 3 months using a 6‐point global improvement scale, and adverse events (AE) were recorded at each visit. Results: Overall, 325 patients were enrolled from 52 investigational centres, 314 of whom attended the 3‐month visit. Most patients had multiple lesions (58.4% had >10 lesions) with lesions mainly located on the scalp (60.0%) and/or forehead (54.2%). AKs were predominantly grade I (39.4%) or grade II (33.2%), and 10.5% of patients had grade III lesions. The proportions of patients and physicians that were overall satisfied to very satisfied with the MAL DL‐PDT treatment were 80.4% and 90.3%, respectively. The vast majority of patients (90.0%) would consider using MAL DL‐PDT again if needed. Physician‐assessed efficacy at 3 months was at least much improved in 83.5% of patients, with 45.9% of patients requiring no retreatment. Related AEs were reported in 15% of patients. Conclusion: Use of MAL DL‐PDT for multiple face and/or scalp AKs resulted in high levels of patient and physician satisfaction in clinical practice in Europe, reflecting the good efficacy and high tolerability of this convenient procedure.